


# (12) UK Patent Application (19) GB (11) 2 060 620 A

- (21) Application No **8028713**  
 (22) Date of filing **5 Sep 1980**  
 (30) Priority data  
 (31) **7932046**  
 (32) **14 Sep 1979**  
 (33) **United Kingdom (GB)**  
 (43) Application published  
**7 May 1981**  
 (51) **INT CL<sup>3</sup>**  
**C07C 93/14 A61K 31/135**  
 (52) Domestic classification  
**C2C 220 226 227 22Y**  
**290 29X 29Y 30Y 311**  
**31Y 322 323 32Y 332 364**  
**36Y 500 50Y 620 621 624**  
**650 661 662 682 694 699**  
**802 80Y AA LF LW**  
 (56) Documents cited  
**GB 1493961 (Eli Lilly)**  
**J. Pharmacor Exy The 193**  
**804—11 (1975)**  
**J. Pharm. Soc. Japan 93**  
**508—19 (1973)**  
**JP 7700941A**  
**(cf CA 87 (P) 5817c)**  
 (58) Field of search  
**C2C**  
 (71) Applicants  
**John Wyeth & Brother**  
**Limited, Huntercombe**  
**Lane South, Taplow,**  
**Maidenhead, Berkshire,**  
**England**  
 (72) Inventor  
**Robin Gerald Shepherd**  
 (74) Agent  
**K. J. S. Brown, c/o Wyeth**  
**Laboratories,**  
**Huntercombe Lane South,**  
**Taplow, Maidenhead,**  
**Berkshire, England**

## (54) 3-Aryl-3-aryloxypropylamines

(57) 3-Aryl-3-aryloxypropylamines of the general formula (I)



and their pharmaceutically acceptable

acid addition salts, wherein R<sup>1</sup> and R<sup>2</sup> are hydrogen or lower alkyl, R<sup>3</sup> is hydrogen, lower alkyl or benzyl, R<sup>4</sup> is hydrogen or lower alkyl, Ar is a phenyl group substituted by at least one trifluoromethyl, lower alkyl, lower alkoxy, nitro or amino group and Ar<sup>1</sup> is a phenyl radical optionally substituted by one or more trifluoromethyl, lower alkyl, lower alkenyl, halogen, nitro, amino or acylamino groups exhibit activity on the central nervous system, e.g. as antidepressants.

Certain of the chemical formulae appearing in the printed specification were submitted in formal form after the date of filing.


GB 2 060 620 A

## SPECIFICATION

## 3-Aryl-3-aryloxypropylamines


This invention relates to 3-aryl-3-arylpropylamines, to a process for preparing them, to their use and to pharmaceutical preparations containing them.

5 The present invention provides 3-aryl-3-aryloxypropylamines of the general formula (I) 5



and their pharmaceutically acceptable acid addition salts, wherein R<sup>1</sup> and R<sup>2</sup> are hydrogen or lower alkyl, R<sup>3</sup> is hydrogen, lower alkyl or benzyl, R<sup>4</sup> is hydrogen or lower alkyl, Ar is a phenyl group substituted by at least one trifluoromethyl, lower alkyl, lower alkoxy, nitro or amino group and Ar<sup>1</sup> is a phenyl radical optionally substituted by one or more trifluoromethyl, lower alkyl, lower alkenyl, halogen, nitro, amino or acylamino groups. 10 10

The invention also provides a process for preparing a compound of general formula (I) or a pharmaceutically acceptable acid addition salt thereof, which comprises reacting an anion of an alcohol of general formula (II)



(where Ar, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined above) with a halo compound of general formula (III)



where X is fluorine and Ar<sup>1</sup> is an optionally substituted phenyl radical as defined above other than an amino or acylamino substituted phenyl. The reaction may be carried out in a dipolar aprotic solvent. 20 Examples of dipolar aprotic solvents include dimethylsulphoxide, dimethylformamide, hexamethylphosphoric triamide and sulfolane. Preferably the solvent is dimethylsulphoxide. The anion of the alcohol of general formula (II) is preferably formed by reacting the alcohol with potassium or sodium hydride or an alkyl or phenyl lithium (e.g. butyl lithium) in a compatible dipolar aprotic solvent. Preferably the alcohol is reacted with sodium hydride. 25

The process of the invention can be carried out at convenient temperatures e.g. 0 to 100°C (for example room temperature); there is generally no need to use reflux temperatures. Good yields of products are generally obtained in relatively short reaction times (e.g. within two to three hours).

If in the process described above the compound of the general formula (I) is obtained as an acid addition salt, such as pharmaceutically acceptable acid addition salt or an acid addition salt such as an oxalate, the free base can be obtained by basifying a solution of the acid addition salt. Conversely, if the product of the process is a free base a pharmaceutically acceptable acid addition salt may be obtained by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with the conventional procedures for preparing acid addition salts from base compounds. 30 30

Examples of acid addition salts are those formed from inorganic and organic acids, such as sulphuric, hydrochloric, hydrobromic, phosphoric, tartaric, fumaric, maleic, citric, acetic, formic, methanesulphonic and p-toluenesulphonic acids. 35 35

Once a compound of general formula (I) is obtained, if desired it can be converted into another compound of general formula (I) by known methods. For example, a 3-aryl-3-aryloxypropylamine of formula (I) in which both R<sup>3</sup> and R<sup>4</sup> are methyl can be converted to the compound in which one group is methyl and the other hydrogen by treatment with cyanogen bromide or ethyl or phenyl chloroformate followed by basic hydrolysis. Further a compound of formula (I) in which Ar<sup>1</sup> is a nitrophenyl group can be reduced to a compound in which Ar<sup>1</sup> is an aminophenyl. The aminophenyl substituent can be acylated to an acylaminophenyl substituent or may be diazotised and converted to standard procedures to a halophenyl, alkoxyphenyl or unsubstituted phenyl substituent. 40 40

The compounds of general formula (I) possess one or more asymmetric carbon atoms, depending upon the particular substituents. The compounds can therefore exist in various stereochemical forms. It will be realised that if the starting material of formula (II) is a mixture of isomers the product of formula (I) will also be a mixture of isomers which may be separated, if required, by standard procedures. If the starting material is a single isomer then the product will also be a single isomer. 45 45

The term "lower" as used herein means that the radical referred to contains 1 to 6 carbon atoms. The radical preferably contains 1 to 4 carbon atoms. Examples of lower alkyl radicals include methyl, 50 50

ethyl, propyl and butyl. Examples of lower alkoxy radicals include methoxy, ethoxy, propoxy and butoxy. Examples of lower alkenyl radicals include allyl and methallyl. When R<sup>1</sup>, R<sup>2</sup> and/or R<sup>3</sup> represent lower alkyl, the lower alkyl group is preferably a straight chain radical such as methyl, ethyl, n-propyl or n-butyl although R<sup>3</sup> may also be, for example, a branched chain lower alkyl group such as isopropyl. When Ar<sup>1</sup> is substituted by halogen, the halogen may be fluoro, chloro, bromo or iodo. When Ar<sup>1</sup> is substituted by acylamino the substituent can be, for example, acetamido.

The compounds of general formula (I) and their pharmaceutically acceptable acid addition salts, including the novel compounds of the invention, generally possess pharmacological activity. In particular the compounds exhibit activity on the central nervous system, e.g. as antidepressants, as indicated by one or more of the standard pharmacological test procedures such as the reserpine hypothermia procedure based upon B. M. Askew, Life Sciences (1963), 1, 725—730, the inhibition of noradrenaline or 5-hydroxytryptamine uptake in rat brain slices, the potentiation and prolongation of the effects of amphetamine and the modification of the effects of p-chloroamphetamine. For example, N,N-dimethyl-3-(4-methylphenyl)-3-(4-nitrophenoxy)propylamine, a representative compound of the invention, produced potentiation of amphetamine-induced stereotypy in rats (Quinton et al, Nature, 1963, 200, 178—179) at 50 mg/kg per os.

The invention further provides a method of treating depression which comprises administering to a warm blooded mammal particularly a human, a therapeutically effective amount of a compound of the invention. The invention also provides a pharmaceutical composition comprising a novel compound of the invention in association with a pharmaceutically acceptable carrier. Any suitable carrier known in the art can be used to prepare the pharmaceutical compositions. In such a composition, the carrier may be a solid, liquid or mixture of a solid and a liquid. Solid form compositions include powders, tablets and capsules. A solid carrier can be one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets the active ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from 5 to 99, preferably 10—80% of the active ingredient. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, and cocoa butter. The term "composition" is intended to include the formulation of an active ingredient with encapsulating material as carrier to give a capsule in which the active ingredient (with or without other carriers) is with it. Similarly cachets are included.

Sterile liquid form compositions include sterile solutions, suspensions, emulsions, syrups and elixirs. The active ingredients can be dissolved or suspended in a pharmaceutically acceptable sterile liquid carrier, such as sterile water, sterile organic solvent or a mixture of both. Preferably a liquid carrier is one suitable for parenteral injection. Where the active ingredient is sufficiently soluble it can be dissolved in normal saline as a carrier; if it is too insoluble for this it can often be dissolved in a suitable organic solvent, for instance aqueous propylene glycol or polyethylene glycol solutions. Aqueous propylene glycol containing from 10 to 75% of the glycol by weight is generally suitable. In other instances other compositions can be made by dispersing the finely-divided active ingredient in aqueous starch or sodium carboxymethyl cellulose solution, or in a suitable oil, for instance arachis oil. Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilised by intramuscular, intraperitoneal or subcutaneous injection. In many instances a compound is orally active and can be administered orally either in liquid or solid composition form.

Preferably the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit doses containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example packeted powders or vials or ampoules. The unit dosage form can be a capsule, cachet or tablet itself, or it can be the appropriate number of any of these in package form. The quantity of the active ingredient in a unit dose of composition may be varied or adjusted from 5 mg. or less to 500 mg. or more, according to the particular need and the activity of the active ingredient. The invention also includes the compounds in the absence of the carrier where the compounds are in unit dosage form.

#### EXAMPLE 1

N,N-Dimethyl-3-(4-methylphenyl)-3-(4-nitrophenoxy)propylamine

A mixture of N,N-dimethyl-3-hydroxy-3-(4-methylphenyl) propylamine (3.86 g, 20 mM), 50% sodium hydride dispersion (1 g) and DMSO (50 ml) was heated at 80° until homogenous, cooled to room temperature and treated dropwise with a solution of 4-fluoronitrobenzene (2.82 g, 20 mM) in DMSO (20 ml) with cooling (exothermic). After 1 h the reaction mixture was poured on to water (200 ml) and extracted with ether (2 × 200 ml). The ether layer was extracted with 1 N hydrochloric acid (2 × 50 ml), the acid layer basified and extracted with ether (2 × 200 ml). The organic layer was dried and the solvent removed under reduced pressure. The residue was dissolved in ethyl acetate and treated with an excess of a solution of oxalic acid dihydrate in ethyl acetate. The resulting precipitate was removed by filtration, washed well with acetone and dried in vacuo to give the title compound as

the oxalate hydrate (4 g). m.p. 188—190° (d).

Found: C 58.5; H 6.0; N 6.7%

$C_{18}H_{22}N_2O_3 \cdot C_2H_2O_4 \cdot \frac{1}{4}H_2O$  requires: C 58.7; H 6.0; N 6.9%.


#### EXAMPLES 2—4

5 The stated products are prepared, following the procedure of Example 1, by reacting the alcohol with sodium hydride and treating the resulting anion with the halo compound. 5

Example	Alcohol	Halo Compound	Product	
10 2	N-methyl-3-hydroxy-3-(4-methylphenyl)propylamine	4-fluorobenzo-trifluoride	N-methyl-3-(4-methylphenyl)-3-(4-trifluoromethylphenoxy)-propylamine	10
15 3	N,N-dimethyl-3-hydroxy-3-(4-trifluoromethylphenyl)propylamine	4-fluorotoluene	N,N-dimethyl-3-(4-trifluoromethylphenyl)-3-(4-methylphenoxy)-propylamine	15
4	N,N-dimethyl-3-hydroxy-3-(4-methoxyphenyl)propylamine	4-fluoronitrobenzene	N,N-dimethyl-3-(4-methoxyphenyl)-3-(4-nitrophenoxy)-propylamine	

#### 20 CLAIMS

1. A 3-aryl-3-aryloxypropylamine of the general formula (I) 20



or a pharmaceutically acceptable acid addition salt thereof wherein R<sup>1</sup> and R<sup>2</sup> are hydrogen or lower alkyl, R<sup>3</sup> is hydrogen, lower alkyl or benzyl, R<sup>4</sup> is hydrogen or lower alkyl, Ar is a phenyl group substituted by at least one trifluoromethyl, lower alkyl, lower alkoxy, nitro or amino group and Ar<sup>1</sup> is a phenyl radical optionally substituted by one or more trifluoromethyl, lower alkyl, lower alkenyl, halogen, nitro, amino or acylamino groups. 25

2. A compound as claimed in claim 1 wherein Ar<sup>1</sup> is a phenyl radical substituted by a nitro or trifluoromethyl group.


30 3. A compound as claimed in claim 1 or 2 wherein Ar is a phenyl radical substituted by a lower alkyl group. 30

4. N,N-Dimethyl-3-(4-methylphenyl)-3-(4-nitrophenoxy)-propylamine or a pharmaceutically acceptable acid addition salt thereof.

35 5. A process for preparing a compound claimed in claim 1 which comprises reacting an anion of an alcohol of general formula (II) 35



(wherein Ar, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined in claim 1) with a halo compound of general formula (III)



40 where X is fluorine and Ar<sup>1</sup> is an optionally substituted phenyl radical as defined in claim 1 other than an amino or acylamino substituted phenyl, if required reducing a product in which Ar<sup>1</sup> is a phenyl group substituted by nitro to a compound in which Ar<sup>1</sup> is substituted by amino and if required acylating the amino substituent to an acylamino substituent, and, if desired, converting a free base of general formula (I) into a pharmaceutically acceptable acid addition salt thereof. 40

45 6. A process as claimed in claim 5 where the anion of the alcohol of general formula (II) is formed by reacting the alcohol with potassium or sodium hydride or with an alkyl or phenyl lithium. 45

7. A process for preparing a compound claimed in claim 1 substantially as hereinbefore described with reference to any one of the Examples.

8. A compound as claimed in claim 1 whenever prepared by the process claimed in any one of claims 5 to 7.

5 9. A pharmaceutical composition comprising a compound claimed in any one of claims 1 to 4 and 8 in association with a pharmaceutically acceptable carrier. 5

10. A compound claimed in any one of claims 1 to 4 and 8 for use as an antidepressant.

---

Printed for Her Majesty's Stationery Office by the Courier Press, Leamington Spa, 1981. Published by the Patent Office,  
25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.